Vioxx Withdrawal Shows Need To “Reconsider” FDA Approval Process – Kessler
This article was originally published in The Pink Sheet Daily
Executive Summary
Former FDA commissioner says agency may “need to be more careful” in its reviews of drugs for less serious conditions during interview broadcast by National Public Radio. “It certainly is a time for reconsideration” of FDA’s approach to drug approvals and post-marketing safety, Kessler says.